Products & safety
3-MCPD: free and ester forms, sauces and refined oils, intake models and infant context
On this page
3-MCPD is a process contaminant, meaning it can form unintentionally during food manufacturing or heating. Free and fatty-acid-bound forms require distinction. The similar names 2-MCPD and glycidyl esters describe different substances, so their evidence and limits cannot be exchanged.[1]
The number identifies a chemical structure
3-MCPD means 3-monochloropropane-1,2-diol, a chloropropanol. Its chlorine position differs from 2-MCPD. Free 3-MCPD and fatty-acid esters are related forms: esters attach it to fatty acids and can release it during digestion. They are not identical to glycidyl esters, which release glycidol.[1]
Acid-hydrolyzed protein is a particular manufacturing route
FDA's sauce guidance addresses free 3-MCPD associated with acid-hydrolyzed protein, a manufacturing process that breaks protein down using acid. It is not a blanket assessment of all soy sauces or all fermented foods. The guidance specifies dry or liquid reporting bases depending on the material. Those distinctions matter when comparing a seasoning ingredient with a ready-to-use sauce. A category name or salt content cannot identify the contaminant concentration; appropriate analytical testing is needed.[3]
Esters can form during refining
FDA describes formation of 3-MCPD esters during high-temperature oil refining intended to remove unwanted tastes, colors and odors. They can occur in palm oils but also other refined vegetable and marine oils. Oil identity alone therefore cannot establish absence or quantify a finished product. Manufacturing conditions, mitigation and how much oil enters the food affect the exposure question. Dietary intake involves the concentration in the consumed product, the portion and frequency, rather than simply counting refined ingredients on a label.[2]
Ask which forms and food matrix were analyzed
FDA researchers developed a method to extract esters from infant formula and analyze them using liquid chromatography with tandem mass spectrometry. The published abstract describes validation and recovery testing in specified formula preparations. Analytical performance is a separate question from clinical harm: identifying a contaminant does not show that an infant developed an adverse effect. A report should preserve free versus bound forms, equivalent units, preparation basis and relevant method scope. A test for free 3-MCPD alone should not be silently treated as a total-ester measurement.[6]
Evidence & uncertainty
Selected agency guidance and analytical studies explain formation and exposure assessment. Most hazard evidence used for the daily intake benchmark comes from animals. A product concentration, a modeled daily intake and an observed human health outcome are different findings.[4]
Selected-source overview · Independent review pendingPublished questions
What does 3-MCPD stand for?
Selected-source overview · Independent review pending. Read the evidence context.
It is 3-monochloropropane-1,2-diol, a chloropropanol. The number distinguishes its chemical structure from 2-MCPD.[1]
Evidence behind this answer
- Health risks from 3-MCPD, 2-MCPD and glycidyl fatty acid esters
agency guidance or assessment · 2025
Original official page and selected relevant passages inspected; no independent expert review · Chemical definitions, free versus esters, formation; infant-feeding advice
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does all soy sauce have the same 3-MCPD issue?
Selected-source overview · Independent review pending. Read the evidence context.
No. FDA's guidance addresses particular acid-hydrolyzed-protein contexts. Fermentation labels and food names cannot substitute for process and analytical information.[3]
Evidence behind this answer
- CPG 500.500: Guidance Levels for 3-MCPD in Acid-Hydrolyzed Protein and Asian-Style Sauces
agency guidance or assessment · 2017
Original FDA guidance PDF selected background and policy inspected; nonbinding case-by-case enforcement context · Background and policy: acid-hydrolyzed protein, 1 ppm guidance with dry/liquid basis and case-by-case enforcement
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is the concern limited to palm oil?
Selected-source overview · Independent review pending. Read the evidence context.
No. FDA identifies other refined vegetable and marine oils too. Particular concentration and manufacturing conditions matter more than an oil name alone.[2]
Evidence behind this answer
- 3-MCPD Esters and Glycidyl Esters
agency guidance or assessment · 2024
Original official page and selected relevant passages inspected; no independent expert review · Formation during oil refining; multiple oil sources; digestion and surveillance
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a free-3-MCPD test measure every ester?
Selected-source overview · Independent review pending. Read the evidence context.
Not automatically. Analytical methods distinguish chemical forms and sample preparation. The formula-method study specifically extracts and measures esters.[6]
Evidence behind this answer
- Extraction and LC-MS/MS Detection of 3-MCPD Esters and Glycidyl Esters in Infant Formula
primary analytical research · 2016
Original research abstract indexed by PubMed inspected; complete methods and validation data not independently reanalyzed · Original analytical-study abstract: extraction, matrix-specific validation and recovery
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is the EFSA number a personal poisoning threshold?
Selected-source overview · Independent review pending. Read the evidence context.
No. It is a body-weight-based group intake benchmark derived from animal evidence with uncertainty allowances, intended for repeated-exposure assessment.[4]
Evidence behind this answer
- Update of the risk assessment on 3-monochloropropane diol and its fatty acid esters
agency guidance or assessment · 2018
Original agency assessment summary and selected conclusions inspected; underlying animal data not independently reanalyzed · Summary and conclusions: kidney endpoint, 2 micrograms/kg/day group TDI, modeling divergence and gaps
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Should I replace formula with a homemade substitute?
Selected-source overview · Independent review pending. Read the evidence context.
BfR advises continuing appropriate formulated infant feeds when breastfeeding is not used. Nutritional adequacy matters while manufacturers and regulators reduce contaminants.[1]
Evidence behind this answer
- Health risks from 3-MCPD, 2-MCPD and glycidyl fatty acid esters
agency guidance or assessment · 2025
Original official page and selected relevant passages inspected; no independent expert review · Chemical definitions, free versus esters, formation; infant-feeding advice
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
The daily benchmark is built from animal evidence
EFSA's 2018 update used kidney effects in rats to derive a group tolerable daily intake of 2 micrograms per kilogram of body weight for 3-MCPD and its esters, expressed as equivalents. It also considered male reproductive effects. EFSA changed its earlier value after revisiting dose-response modeling and differences with JECFA. This is a protective assessment benchmark for continuing exposure, not a recommended intake or a proven human injury threshold. Animal-to-human translation, developmental data and model choices remain important limits.[4]
High intake per body weight needs attention
EFSA's revised assessment described potential concern for younger high consumers and a worst-case scenario for infants receiving formula only. This means a dietary pattern and body-weight context affected modeled exposure; it does not mean every formula feeding causes harm. Infants depend on nutritionally adequate feeds, so contaminant mitigation is principally a manufacturing and regulatory task. The risk assessment does not support replacing formula with a nutritionally unsuitable drink or diluting it differently from its instructions.[5]
Older concentration surveys are not current brand grades
A 2020 FDA-researcher survey analyzed 222 US infant formulas purchased in 2017-2019 and compared them with an earlier survey. Results varied across manufacturers and suggested reductions in several groups. These are chemical-occurrence findings, not trials measuring infant health outcomes. They also do not establish today's concentration in a named product. Sampling dates, manufacturing changes and the basis of comparison need to remain attached whenever historical data are used to explain the possibility of mitigation.[7]
A legal concentration and daily intake differ
FDA's sauce guidance uses 1 part per million in a specified enforcement context and allows case-by-case decisions; that number is not an infant-formula allowance. European requirements also continue to change: the August 2026 consolidated text identifies a 2026 amendment and a 1 January 2027 transition for specified 3-MCPD and glycidyl provisions. Check the applicable category, date and reporting basis. Complete amended legal tables were not extracted for this explanation, so it supplies no product compliance certificate.[3][8]
References
- Health risks from 3-MCPD, 2-MCPD and glycidyl fatty acid esters
Agency guidance or assessment
German Federal Institute for Risk Assessment (BfR) · Content/publication date: 2025
Accessed: 2026-10-13 UTC · Original official page and selected relevant passages inspected; no independent expert review
Cited sections: Chemical definitions, free versus esters, formation; infant-feeding advicePublication or content date is distinct from access date; no claim of continuous monitoring.
- 3-MCPD Esters and Glycidyl Esters
Agency guidance or assessment
US FDA · Content/publication date: 2024
Accessed: 2026-10-13 UTC · Original official page and selected relevant passages inspected; no independent expert review
Cited sections: Formation during oil refining; multiple oil sources; digestion and surveillancePublication or content date is distinct from access date; no claim of continuous monitoring.
- CPG 500.500: Guidance Levels for 3-MCPD in Acid-Hydrolyzed Protein and Asian-Style Sauces
Agency guidance or assessment
US FDA · Content/publication date: 2017
Accessed: 2026-10-13 UTC · Original FDA guidance PDF selected background and policy inspected; nonbinding case-by-case enforcement context
Cited sections: Background and policy: acid-hydrolyzed protein, 1 ppm guidance with dry/liquid basis and case-by-case enforcementPublication or content date is distinct from access date; no claim of continuous monitoring.
- Update of the risk assessment on 3-monochloropropane diol and its fatty acid esters
Agency guidance or assessment
EFSA CONTAM Panel · Content/publication date: 2018
Accessed: 2026-10-13 UTC · Original agency assessment summary and selected conclusions inspected; underlying animal data not independently reanalyzed
Cited sections: Summary and conclusions: kidney endpoint, 2 micrograms/kg/day group TDI, modeling divergence and gapsPublication or content date is distinct from access date; no claim of continuous monitoring.
- Revised safe intake for 3-MCPD in vegetable oils and food
Agency guidance or assessment
EFSA · Content/publication date: 2018
Accessed: 2026-10-13 UTC · Original official page and selected relevant passages inspected; no independent expert review
Cited sections: 2018 revised assessment, younger high consumers and formula-only exposure scenariosPublication or content date is distinct from access date; no claim of continuous monitoring.
- Extraction and LC-MS/MS Detection of 3-MCPD Esters and Glycidyl Esters in Infant Formula
Primary analytical research
Leigh JK, MacMahon S / US FDA researchers · Content/publication date: 2016
Accessed: 2026-10-13 UTC · Original research abstract indexed by PubMed inspected; complete methods and validation data not independently reanalyzed
Cited sections: Original analytical-study abstract: extraction, matrix-specific validation and recoveryPublication or content date is distinct from access date; no claim of continuous monitoring.
- Updated occurrence of 3-MCPD esters and glycidyl esters in US infant formulas, 2017-2019
Primary analytical research
Beekman JK, Grassi K, MacMahon S / US FDA researchers · Content/publication date: 2020
Accessed: 2026-10-13 UTC · Original research abstract indexed by PubMed inspected; underlying product-level dataset not independently reanalyzed
Cited sections: Original survey abstract: 222 samples, manufacturers and temporal comparison limitsPublication or content date is distinct from access date; no claim of continuous monitoring.
- Regulation (EU) 2023/915: consolidated text of 19 August 2026
Agency guidance or assessment
European Union / EUR-Lex · Content/publication date: 2026
Accessed: 2026-10-13 UTC · Official indexed excerpts inspected; direct HTML/PDF retrieval blocked by anti-bot verification. Complete numerical tables and full legal applicability not extracted
Cited sections: Indexed official consolidated-text excerpt: 2026/1825 amendment and 1 January 2027 transition for specified 3-MCPD/glycidyl provisionsPublication or content date is distinct from access date; no claim of continuous monitoring.
Scope & review
- Population
- General readers; vulnerable populations and source-specific exposure settings are distinguished
- Exposure or intervention
- 3-MCPD
- Comparison
- Chemical forms, exposure routes, source-specific populations and jurisdiction-specific rules
- Outcomes
- Definitions, categories, exposure interpretation, practical questions and uncertainty
- Timeframe
- Selected historical and current sources checked 2026-10-13; publication dates are recorded separately
- Jurisdiction
- US and explicitly identified international guidance; local requirements differ
Bounded selected-source educational explanation. Agency assessments and editorial interpretation are distinguished; no exhaustive search, independent systematic synthesis or qualified medical review.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-13 UTC: Added definition-first explainer with exposure distinctions, source-linked questions and uncertainty.
What this article still leaves open
- No current formula brand ranking, complete EU legal table or individualized intake calculation is provided.
- Clinical developmental evidence, the appropriate interpretation of historical surveys and full current law need further appraisal.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.